FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

KalVista Pharmaceuticals KALV saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 62 to 90. Please watch the video at Investors.com - Do Your Stocks Meet ...

KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

KalVista's journey to FDA approval wasn't smooth sailing, with an unexpected delay and alleged behind-the-scenes drama at the ...

KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...

The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...